Lucid Diagnostics price target raised to $9 from $8.25 at Ascendiant

Ascendiant analyst Edward Woo raised the firm’s price target on Lucid Diagnostics (LUCD) to $9 from $8.25 and keeps a Buy rating on the shares post the Q4 report. The firm says the company’s “high growth” and Medicare coverage starting should drive the stock “much higher.”